Abstract

The successful ex vivo expansion of a large numbers of T cells is a prerequisite for adoptive immunotherapy. In this study, we found that cell density had important effects on the process of expansion of T cells in vitro. Resting T cells were activated to expand at high cell density but failed to be activated at low cell density. Activated T cells (ATCs) expanded rapidly at high cell density but underwent apoptosis at low cell density. Our studies indicated that low-cell-density related ATC death is mediated by oxidative stress. Antioxidants N-acetylcysteine, catalase, and albumin suppressed elevated reactive oxygen species (ROS) levels in low-density cultures and protected ATCs from apoptosis. The viability of ATCs at low density was preserved by conditioned medium from high-density cultures of ATCs in which the autocrine survival factor was identified as catalase. We also found that costimulatory signal CD28 increases T cell activation at lower cell density, paralleled by an increase in catalase secretion. Our findings highlight the importance of cell density in T cell activation, proliferation, survival and apoptosis and support the importance of maintaining T cells at high density for their successful expansion in vitro.

Highlights

  • T cells are a critical component of the cellular immune response

  • The viability of Activated T cells (ATCs) at low density was preserved by conditioned medium from high-density cultures of ATCs in which the autocrine survival factor was identified as catalase

  • This includes the early studies with lymphokine-activated killer (LAK) cells derived from ex vivo amplification of autologous lymphocytes with interleukin-2 (IL-2), late studies with tumor infiltrating lymphocytes (TILs) isolated from tumor specimens, and recent studies with genetically modified tumor reactive T cells [2]

Read more

Summary

Introduction

In the past two decades, adoptive transfer of tumor reactive T cells into cancer patients has been created as an immunotherapy method to combat cancer [1]. This includes the early studies with lymphokine-activated killer (LAK) cells derived from ex vivo amplification of autologous lymphocytes with interleukin-2 (IL-2), late studies with tumor infiltrating lymphocytes (TILs) isolated from tumor specimens, and recent studies with genetically modified tumor reactive T cells [2]. The ex vivo expansion of T cells for adoptive immunotherapy usually involves two phases. The first phase is T cell activation, in which resting T cells are activated with anti-CD3 antibody or plus anti-CD28 antibody supplemented with IL-2.

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.